Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Purpose
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Condition
- Prostate Adenocarcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of the prostate within 270 days prior to registration - Unfavorable intermediate risk prostate cancer, defined as having ALL the following bulleted criteria: - Has at least one intermediate risk factor (IRF): - PSA 10-20 ng/mL - Clinical stage T2b-c (digital rectal examination [DRE] and/or imaging) by American Joint Committee on Cancer (AJCC) 8th edition - Gleason score 7 (Gleason 3+4 or 4+3 [ International Society of Urological Pathology (ISUP) Grade Group 2-3]) - Has ONE or more of the following 'unfavorable' intermediate-risk designators: - > 1 immature reticulocyte fraction (IRF) - Gleason 4+3=7 (ISUP Grade Group 3) - >= 50% of biopsy cores positive - Biopsies may include 'sextant' sampling of right/left regions of the prostate, often labeled base, mid-gland and apex. All such 'sextant' biopsy cores should be counted. Men may also undergo 'targeted' sampling of prostate lesions (guided by MRI, ultrasound or other approaches). A targeted lesion that is biopsied more than once and demonstrates cancer (regardless of number of targeted cores involved) should count as a single additional positive core sampled and positive. In cases of uncertainty, count the biopsy sampling as sextant core(s) - Absence of high-risk features - Appropriate stage for study entry based on the following diagnostic workup: - History/physical examination within 120 days prior to registration; - Negative bone imaging (M0) within 120 days prior to registration; Note: Tc-99m bone scan or sodium fluoride (NaF) positron emission tomography (PET) are allowed. Equivocal bone scan findings are allowed if plain films X-ray, computed tomography (CT) or magnetic resonance imaging (MRI) are negative for metastasis at the concerned site(s). While a negative fluciclovine, choline, or prostate specific membrane antigen (PSMA) PET may be counted as acceptable substitute for bone imaging, any suspicious findings must be confirmed and correlated with conventional imaging (Tc-99m bone scan, NaF PET, CT, X-ray, or MRI) to determine eligibility based on the latter modalities (e.g. M0 based on conventional imaging modalities) - Clinically negative lymph nodes (N0) as established by conventional imaging (pelvic +/- abdominal CT or MR), within 120 days prior to registration. Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are =< 1.0 cm in short axis and/or if biopsy is negative. Note: While a negative fluciclovine, choline, or prostate specific membrane antigen (PSMA) PET may be counted as acceptable substitute for pelvic imaging, any suspicious findings must be confirmed by conventional imaging (CT, MRI or biopsy). If the findings do not meet pathological criteria based on the latter modalities (e.g. node =< 10 mm in short axis, negative biopsy), the patient will still be eligible - Age >= 18 - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 120 days prior to registration - Non-castrate testosterone level (> 50 ng/dL) within 120 days prior to registration - Absolute neutrophil >= 1,000 cells/mm^3 (within 120 days prior to registration) - Hemoglobin >= 8.0 g/dL, independent of transfusion and/or growth factors (within 120 days prior to registration) - Platelet count >= 100,000 cells/mm^3 independent of transfusion and/or growth factors (within 120 days prior to registration) - Creatinine clearance (CrCl) >= 30 mL/min estimated by Cockcroft-Gault equation (within 120 days prior to registration) - For African American patients specifically whose renal function is not considered adequate by the formula above, an alternative formula that takes race into account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) should be used for calculating the related estimated glomerular filtration rate (GFR) with a correction factor for African American race creatinine clearance for trial eligibility, where GFR >= 30 mL/min/1.73m^2 will be considered adequate - Total bilirubin: 1.5 =< institutional upper limit of normal (ULN) (within 120 days prior to registration) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is less than or equal to 1.5 x ULN, subject is eligible) - Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]): =< 2.5 x institutional ULN (within 120 days prior to registration) - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial; Note: HIV testing is not required for eligibility for this protocol - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. - Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B) - For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Previous radical surgery (prostatectomy) or any form of curative-intent ablation whether focal or whole-gland (e.g., cryosurgery, high intensity focused ultrasound [HIFU], laser thermal ablation, etc.) for prostate cancer - Definitive clinical or radiologic evidence of metastatic disease (M1) - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years. History of or current diagnosis of hematologic malignancy is not allowed - Prior radiotherapy to the prostate/pelvis region that would result in overlap of radiation therapy fields - Previous bilateral orchiectomy - Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate). ADT started prior to study registration is not allowed - Prior use of 5-alpha-reductase inhibitors is allowed, however, it must be stopped prior to enrollment on the study with at least a 30 day washout period before baseline study PSA measure and registration - Active testosterone replacement therapy; any replacement therapy must be stopped at least 30 days prior to registration - Severe, active co-morbidity defined as follows: - Current severe or unstable angina; - New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification) - History of any condition that in the opinion of the investigator, would preclude participation in this study - Inability to swallow oral pills - High risk features, which includes any of the following: - Gleason 8-10 [ISUP Grade Group 4-5] - PSA > 20 - cT3-4 by digital exam OR gross extra-prostatic extension on imaging [indeterminate MRI evidence will not count and the patient will be eligible]
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Arm I (RT) |
Patients undergo radiation therapy (RT) using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm II (RT, ADT) |
Patients undergo RT as Arm I. Patients also receive androgen deprivation therapy (ADT) consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days. |
|
Experimental Arm III (RT, ADT) |
Patients receive treatment as in Arm II. |
|
Experimental Arm IV (RT, ADT, darolutamide) |
Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Birmingham 4049979, Alabama 4829764 35233
Gilbert 5295903, Arizona 5551752 85297
Peoria 5308480, Arizona 5551752 85381
Site Public Contact
623-773-2873
Phoenix 5308655, Arizona 5551752 85027
Surprise 5316428, Arizona 5551752 85374
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Auburn 5325223, California 5332921 95603
Bakersfield 5325738, California 5332921 93301
Site Public Contact
661-323-4673
Beverly Hills 5328041, California 5332921 90211
Cameron Park 5333282, California 5332921 95682
Corona 5339631, California 5332921 92882
Duarte 5344147, California 5332921 91010
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Encinitas 5346646, California 5332921 92024
Site Public Contact
760-536-7700
Fremont 5350734, California 5332921 94538
Fremont 5350734, California 5332921 94538
Site Public Contact
510-745-6433
Fresno 5350937, California 5332921 93720
Greenbrae 5354013, California 5332921 94904
Site Public Contact
415-925-7325
Irvine 5359777, California 5332921 92612
Irvine 5359777, California 5332921 92618
Site Public Contact
877-467-3411
La Jolla 5363943, California 5332921 92093
Lancaster 5364940, California 5332921 93534
Los Angeles 5368361, California 5332921 90033
Los Angeles 5368361, California 5332921 90033
Site Public Contact
323-865-0451
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Marysville 5370984, California 5332921 95901
Site Public Contact
530-749-4400
Modesto 5373900, California 5332921 95355
Modesto 5373900, California 5332921 95356
Napa 5376095, California 5332921 94558
Site Public Contact
707-521-3830
Oakland 5378538, California 5332921 94611
Orange 5379513, California 5332921 92868
Site Public Contact
714-734-6220
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94301
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
Sacramento 5389489, California 5332921 95823
San Diego 5391811, California 5332921 92121
Site Public Contact
858-299-5982
San Diego 5391811, California 5332921 92123
San Francisco 5391959, California 5332921 94115
San Francisco 5391959, California 5332921 94158
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
Santa Barbara 5392952, California 5332921 93105
Santa Clara 5393015, California 5332921 95051
Santa Rosa 5393287, California 5332921 95403
South Pasadena 5397717, California 5332921 91030
South San Francisco 5397765, California 5332921 94080
Sunnyvale 5400075, California 5332921 94086
Tarzana 5401143, California 5332921 91356
Site Public Contact
818-981-3818
Torrance 5403022, California 5332921 90503
Site Public Contact
877-467-3411
Torrance 5403022, California 5332921 90505
Torrance 5403022, California 5332921 90509
Site Public Contact
310-517-4665
Truckee 5403676, California 5332921 96161
Site Public Contact
530-582-6450
Upland 5404915, California 5332921 91786
Vallejo 5405380, California 5332921 94589
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Walnut Creek 5406990, California 5332921 94598
Aurora 5412347, Colorado 5417618 80045
Site Public Contact
720-848-0650
Boulder 5574991, Colorado 5417618 80304
Colorado Springs 5417598, Colorado 5417618 80909
Site Public Contact
719-365-2406
Colorado Springs 5417598, Colorado 5417618 80920
Site Public Contact
719-364-6700
Edwards 5420885, Colorado 5417618 81632
Site Public Contact
970-569-7429
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Fort Collins 5577147, Colorado 5417618 80528
Greeley 5577592, Colorado 5417618 80631
Greeley 5577592, Colorado 5417618 80631
Highlands Ranch 5425043, Colorado 5417618 80129
Site Public Contact
720-848-0650
Loveland 5579368, Colorado 5417618 80538
Site Public Contact
970-203-7083
Loveland 5579368, Colorado 5417618 80539
Bridgeport 5282804, Connecticut 4831725 06606
Site Public Contact
860-972-4700
Greenwich 4835395, Connecticut 4831725 06830
Guilford 4835512, Connecticut 4831725 06437
Hartford 4835797, Connecticut 4831725 06102
Site Public Contact
860-545-5363
Meriden 4838524, Connecticut 4831725 06451
Site Public Contact
866-662-5678
New Britain 4839292, Connecticut 4831725 06050
Site Public Contact
860-224-5660
New Haven 4839366, Connecticut 4831725 06520
Norwalk 4839822, Connecticut 4831725 06856
Trumbull 4844459, Connecticut 4831725 06611
Waterford 8480031, Connecticut 4831725 06385
Millville 4143696, Delaware 4142224 19967
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Rehoboth Beach 4144284, Delaware 4142224 19971
Washington D.C. 4140963, District of Columbia 4138106 20037
Site Public Contact
202-741-2210
Bay Pines 4146855, Florida 4155751 33744
Boca Raton 4148411, Florida 4155751 33486
Site Public Contact
561-955-4800
Gainesville 4156404, Florida 4155751 32610
Jupiter 4160610, Florida 4155751 33458
Site Public Contact
561-745-5768
Weston 4178003, Florida 4155751 33331
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30308
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Decatur 4191124, Georgia 4197000 30033
Gainesville 4196586, Georgia 4197000 30501
Johns Creek 6331909, Georgia 4197000 30097
Savannah 4221552, Georgia 4197000 31405
Honolulu 5856195, Hawaii 5855797 96813
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-532-0315
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-545-8548
Honolulu 5856195, Hawaii 5855797 96813
Site Public Contact
808-522-4333
Honolulu 5856195, Hawaii 5855797 96817
Site Public Contact
808-531-8521
Honolulu 5856195, Hawaii 5855797 96817
Site Public Contact
808-547-6881
‘Aiea 5856430, Hawaii 5855797 96701
‘Aiea 5856430, Hawaii 5855797 96701
Site Public Contact
808-486-6000
‘Ewa Beach 5855051, Hawaii 5855797 96706
Boise 5586437, Idaho 5596512 83712
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Twin Falls 5610810, Idaho 5596512 83301
Alton 4232679, Illinois 4896861 62002
Site Public Contact
618-463-7323
Barrington 4884116, Illinois 4896861 60010
Site Public Contact
847-842-4847
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Chicago 4887398, Illinois 4896861 60657
Site Public Contact
773-296-5360
Crystal Lake 4889229, Illinois 4896861 60014
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Downers Grove 4890119, Illinois 4896861 60515
Effingham 4237727, Illinois 4896861 62401
Elgin 4890864, Illinois 4896861 60123
Site Public Contact
847-429-2907
Elmhurst 4891010, Illinois 4896861 60126
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Geneva 4893591, Illinois 4896861 60134
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
312-695-1102
Grayslake 4894465, Illinois 4896861 60030
Site Public Contact
312-695-1102
Hazel Crest 4895416, Illinois 4896861 60429
Site Public Contact
708-799-9995
Hines 4896005, Illinois 4896861 60141
Site Public Contact
708-202-8387
Kewanee 4898433, Illinois 4896861 61443
Lake Forest 4899012, Illinois 4896861 60045
Libertyville 4899739, Illinois 4896861 60048
Libertyville 4899739, Illinois 4896861 60048
Macomb 4900817, Illinois 4896861 61455
Mattoon 4244099, Illinois 4896861 61938
Maywood 4901514, Illinois 4896861 60153
Site Public Contact
708-226-4357
Naperville 4903279, Illinois 4896861 60540
Site Public Contact
630-646-6075
O'Fallon 4245926, Illinois 4896861 62269
Oak Brook 4904277, Illinois 4896861 60523
Oak Lawn 4904365, Illinois 4896861 60453-2699
Site Public Contact
800-323-8622
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Palos Heights 4905259, Illinois 4896861 60463
Park Ridge 4905367, Illinois 4896861 60068
Site Public Contact
847-384-3621
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61636
Peoria 4905687, Illinois 4896861 61637
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Rockford 4907959, Illinois 4896861 61114
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Warrenville 4915525, Illinois 4896861 60555
Washington 4915545, Illinois 4896861 61571
Cedar Rapids 4850751, Iowa 4862182 52402
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Kansas City 4273837, Kansas 4273857 66160
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Overland Park 4276873, Kansas 4273857 66211
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-270-4939
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Westwood 4281639, Kansas 4273857 66205
Wichita 4281730, Kansas 4273857 67214
Lexington 4297983, Kentucky 6254925 40504
Metairie 4333177, Louisiana 4331987 70002
Site Public Contact
504-584-6990
Metairie 4333177, Louisiana 4331987 70006
Metairie 4333177, Louisiana 4331987 70006
Portland 4975802, Maine 4971068 04102
Rockport 4976817, Maine 4971068 04856
Scarborough 4977882, Maine 4971068 04074
South Portland 4979244, Maine 4971068 04106
Annapolis 4347242, Maryland 4361885 21401
Baltimore 4347778, Maryland 4361885 21201
Baltimore 4347778, Maryland 4361885 21201
Site Public Contact
800-888-8823
Bel Air 4348240, Maryland 4361885 21014
Site Public Contact
443-643-3010
Glen Burnie 4356188, Maryland 4361885 21061
Site Public Contact
410-553-8100
Largo 4360345, Maryland 4361885 20774
Ocean Pines 4364326, Maryland 4361885 21811
Salisbury 4368711, Maryland 4361885 21801
Beverly 4930505, Massachusetts 6254926 01915
Site Public Contact
978-922-3000
Burlington 4931737, Massachusetts 6254926 01805
Gloucester 4937829, Massachusetts 6254926 01930
Site Public Contact
978-283-4000
Peabody 4946863, Massachusetts 6254926 01960
Ann Arbor 4984247, Michigan 5001836 48105
Site Public Contact
800-361-8387
Ann Arbor 4984247, Michigan 5001836 48106
Ann Arbor 4984247, Michigan 5001836 48109
Bay City 4985180, Michigan 5001836 48706
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Brownstown, Michigan 5001836 48183
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Clarkston 4988997, Michigan 5001836 48346
Clarkston 4988997, Michigan 5001836 48346
Clinton Township 4989133, Michigan 5001836 48038
Detroit 4990729, Michigan 5001836 48201
Detroit 4990729, Michigan 5001836 48202
Farmington Hills 4992523, Michigan 5001836 48334
Farmington Hills 4992523, Michigan 5001836 48334
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48532
Grand Rapids 4994358, Michigan 5001836 49503
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49007
Lansing 4998830, Michigan 5001836 48910
Lansing 4998830, Michigan 5001836 48912
Lapeer 4998842, Michigan 5001836 48446
Livonia 4999837, Michigan 5001836 48154
Macomb 5000473, Michigan 5001836 48044
Madison Heights 5000500, Michigan 5001836 48071
Mount Clemens 5002656, Michigan 5001836 48043
Mount Pleasant 5002714, Michigan 5001836 48858
Niles 5003514, Michigan 5001836 49120
Site Public Contact
616-391-1230
Novi 5004062, Michigan 5001836 48377
Petoskey 5005484, Michigan 5001836 49770
Pontiac 5006166, Michigan 5001836 48341
Port Huron 5006233, Michigan 5001836 48060
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Saginaw 5007989, Michigan 5001836 48601
Saint Joseph 5008327, Michigan 5001836 49085
Saint Joseph 5008327, Michigan 5001836 49085
Tawas City 5011900, Michigan 5001836 48764
Traverse City 5012495, Michigan 5001836 49684
Troy 5012639, Michigan 5001836 48085
Site Public Contact
248-551-7695
Troy 5012639, Michigan 5001836 48098
West Bloomfield 7259621, Michigan 5001836 48322
Wyoming 5015618, Michigan 5001836 49519
Ypsilanti 5015688, Michigan 5001836 48197
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Minneapolis 5037649, Minnesota 5037779 55415
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Stillwater 5048814, Minnesota 5037779 55082
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Columbia 4381982, Missouri 4398678 65212
Site Public Contact
573-882-7440
Creve Coeur 4382837, Missouri 4398678 63141
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
Rolla 4406282, Missouri 4398678 65401
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63104
Site Public Contact
314-977-4440
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63136
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Billings 5640350, Montana 5667009 59101
Butte 5642934, Montana 5667009 59701
Site Public Contact
406-723-2621
Great Falls 5655240, Montana 5667009 59405
Bellevue 5063805, Nebraska 5073708 68123
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Lebanon 5088597, New Hampshire 5090174 03756
Basking Ridge 5095409, New Jersey 5101760 07920
Site Public Contact
212-639-7592
Belleville 5095549, New Jersey 5101760 07109
Camden 4501018, New Jersey 5101760 08103
Site Public Contact
856-325-6757
Egg Harbor 8766331, New Jersey 5101760 08234
Site Public Contact
609-748-7200
Elizabeth 5097598, New Jersey 5101760 07207
Site Public Contact
908-994-8000
Englewood 5097672, New Jersey 5101760 07631
Site Public Contact
201-894-3456
Hamilton 5098765, New Jersey 5101760 08690
Site Public Contact
609-631-6946
Jersey City 5099836, New Jersey 5101760 07302
Livingston 5100572, New Jersey 5101760 07039
Middletown 5101170, New Jersey 5101760 07748
Site Public Contact
212-639-7592
Montvale 5101361, New Jersey 5101760 07645
Site Public Contact
212-639-7592
Mount Laurel 4503136, New Jersey 5101760 08054
New Brunswick 5101717, New Jersey 5101760 08903
Site Public Contact
732-235-7356
Newark 5101798, New Jersey 5101760 07101
Site Public Contact
732-235-7356
Newark 5101798, New Jersey 5101760 07112
Paramus 5102387, New Jersey 5101760 07652
Sewell 4504048, New Jersey 5101760 08080
Somerville 5104774, New Jersey 5101760 08876
Toms River 4504476, New Jersey 5101760 08755
Voorhees Township 5105860, New Jersey 5101760 08043
Site Public Contact
856-325-6757
Albuquerque 5454711, New Mexico 5481136 87102
Albuquerque 5454711, New Mexico 5481136 87106
Albuquerque 5454711, New Mexico 5481136 87109
Albuquerque 5454711, New Mexico 5481136 87110
Rio Rancho 5487811, New Mexico 5481136 87124
Bay Shore 5108169, New York 5128638 11706
Site Public Contact
516-734-8896
Brooklyn 5110302, New York 5128638 11215
Buffalo 5110629, New York 5128638 14263
Commack 5113412, New York 5128638 11725
Site Public Contact
212-639-7592
Cooperstown 5113664, New York 5128638 13326
Dansville 5114492, New York 5128638 14437
Flushing 5117472, New York 5128638 11355
Forest Hills 5117575, New York 5128638 11375
Site Public Contact
718-520-6620
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
Greenlawn 5119377, New York 5128638 11740
Site Public Contact
516-734-8896
Harrison 5120095, New York 5128638 10604
Site Public Contact
212-639-7592
Lake Success 5123853, New York 5128638 11042
Site Public Contact
516-734-8896
New York 5128581, New York 5128638 10032
New York 5128581, New York 5128638 10065
Site Public Contact
212-434-4460
New York 5128581, New York 5128638 10065
Site Public Contact
212-639-7592
New York 5128581, New York 5128638 10075
Site Public Contact
516-734-8896
Rego Park 5133640, New York 5128638 11374
Site Public Contact
718-312-3446
Rochester 5134086, New York 5128638 14620
Site Public Contact
585-341-8113
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Sleepy Hollow 5138371, New York 5128638 10591
Site Public Contact
914-366-1600
Staten Island 5139568, New York 5128638 10305
Site Public Contact
718-226-8888
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Syracuse 5140405, New York 5128638 13210
Site Public Contact
315-464-5476
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10467
Uniondale 5141927, New York 5128638 11553
Site Public Contact
212-639-7592
Valhalla 5142090, New York 5128638 10595
Webster 5143495, New York 5128638 14580
Cary 4459467, North Carolina 4482348 27518
Chapel Hill 4460162, North Carolina 4482348 27599
Durham 4464368, North Carolina 4482348 27705
Durham 4464368, North Carolina 4482348 27710
Site Public Contact
888-275-3853
Raleigh 4487042, North Carolina 4482348 27607
Raleigh 4487042, North Carolina 4482348 27609
Raleigh 4487042, North Carolina 4482348 27614
Supply 4830472, North Carolina 4482348 28462
Site Public Contact
910-754-4716
Wilmington 4499379, North Carolina 4482348 28401
Site Public Contact
910-251-1839
Wilmington 4499379, North Carolina 4482348 28401
Site Public Contact
910-342-3000
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Grand Forks 5059429, North Dakota 5690763 58201
Site Public Contact
701-780-6520
Akron 5145476, Ohio 5165418 44304
Akron 5145476, Ohio 5165418 44307
Avon 5146277, Ohio 5165418 44011
Site Public Contact
800-641-2422
Barberton 5146491, Ohio 5165418 44203
Beachwood 5146711, Ohio 5165418 44122
Canton 5149222, Ohio 5165418 44710
Chillicothe 4828890, Ohio 5165418 45601
Cleveland 5150529, Ohio 5165418 44106
Cleveland 5150529, Ohio 5165418 44109
Cleveland 5150529, Ohio 5165418 44111
Cleveland 5150529, Ohio 5165418 44195
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43214
Columbus 4509177, Ohio 5165418 43215
Columbus 4509177, Ohio 5165418 43228
Delaware 5151891, Ohio 5165418 43015
Dublin 5152333, Ohio 5165418 43016
Mansfield 5161723, Ohio 5165418 44903
Mansfield 5161723, Ohio 5165418 44906
Marion 5161902, Ohio 5165418 43302
Mayfield Heights 5162188, Ohio 5165418 44124
Medina 5162512, Ohio 5165418 44256
Mentor 5162645, Ohio 5165418 44060
Parma 5166177, Ohio 5165418 44129
Ravenna 5167737, Ohio 5165418 44266
Sandusky 5170691, Ohio 5165418 44870
Strongsville 5173237, Ohio 5165418 44136
Sylvania 5173572, Ohio 5165418 43560
Warrensville Heights 5175726, Ohio 5165418 44122
Wooster 5177358, Ohio 5165418 44691
Oklahoma City 4544349, Oklahoma 4544379 73104
Bend 5713587, Oregon 5744337 97701
Gresham 5729485, Oregon 5744337 97030
Site Public Contact
503-413-2150
Portland 5746545, Oregon 5744337 97210
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97239
Tualatin 5757506, Oregon 5744337 97062
Site Public Contact
503-413-1742
Allentown 5178127, Pennsylvania 6254927 18104
Site Public Contact
610-776-4714
Altoona 5178195, Pennsylvania 6254927 16601
Beaver 5179446, Pennsylvania 6254927 15009
Bethlehem 5180225, Pennsylvania 6254927 18015
Site Public Contact
484-503-4151
Carlisle 5183234, Pennsylvania 6254927 17015
Chadds Ford 4557084, Pennsylvania 6254927 19317
Chambersburg 4557109, Pennsylvania 6254927 17201
Danville 5186327, Pennsylvania 6254927 17822
Easton 5188140, Pennsylvania 6254927 18045
Ephrata 5188815, Pennsylvania 6254927 17522
Site Public Contact
717-721-4840
Erie 5188843, Pennsylvania 6254927 16505
Erie 5188843, Pennsylvania 6254927 16544
Site Public Contact
814-452-5000
Farrell 5189377, Pennsylvania 6254927 16121
Gettysburg 4558183, Pennsylvania 6254927 17325
Site Public Contact
877-441-7957
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Harrisburg 5192726, Pennsylvania 6254927 17109
Hershey 5193342, Pennsylvania 6254927 17033-0850
Indiana 5194868, Pennsylvania 6254927 15701
Jefferson Hills 5195297, Pennsylvania 6254927 15025
Johnstown 5195561, Pennsylvania 6254927 15901
Site Public Contact
814-534-4724
Lebanon 5197517, Pennsylvania 6254927 17042
Lewisburg 5197842, Pennsylvania 6254927 17837
Meadville 5200644, Pennsylvania 6254927 16335
Mechanicsburg 5200657, Pennsylvania 6254927 17050
Monroeville 5201734, Pennsylvania 6254927 15146
Site Public Contact
412-858-7746
Monroeville 5201734, Pennsylvania 6254927 15146
Monroeville 5201734, Pennsylvania 6254927 15146
Moon Township 5201821, Pennsylvania 6254927 15108
Natrona Heights 5202903, Pennsylvania 6254927 15065
Philadelphia 4560349, Pennsylvania 6254927 19107
Philadelphia 4560349, Pennsylvania 6254927 19114
Philadelphia 4560349, Pennsylvania 6254927 19141
Site Public Contact
215-456-3880
Pittsburgh 5206379, Pennsylvania 6254927 15212
Site Public Contact
877-284-2000
Pittsburgh 5206379, Pennsylvania 6254927 15215
Site Public Contact
412-784-4900
Pittsburgh 5206379, Pennsylvania 6254927 15224
Site Public Contact
412-578-5000
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-621-2334
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
Pittsburgh 5206379, Pennsylvania 6254927 15243
Site Public Contact
412-502-3920
Pottsville 5207080, Pennsylvania 6254927 17901
Quakertown 5207381, Pennsylvania 6254927 18951
Site Public Contact
610-776-4714
Seneca 5211432, Pennsylvania 6254927 16346
Site Public Contact
814-676-7900
Stroudsburg 5214543, Pennsylvania 6254927 18360
Washington 5218069, Pennsylvania 6254927 15301
Washington 5218069, Pennsylvania 6254927 15301
West Reading 5218867, Pennsylvania 6254927 19611
Site Public Contact
610-988-9323
Wexford 5219062, Pennsylvania 6254927 15090
Wilkes-Barre 5219488, Pennsylvania 6254927 18711
Williamsport 5219585, Pennsylvania 6254927 17754
Willow Grove 5219619, Pennsylvania 6254927 19090
York 4562407, Pennsylvania 6254927 17403
Site Public Contact
877-441-7957
York 4562407, Pennsylvania 6254927 17408
Site Public Contact
717-724-6760
Bluffton 4571722, South Carolina 4597040 29910
Charleston 4574324, South Carolina 4597040 29425
Greenville 4580543, South Carolina 4597040 29601
Greenville 4580543, South Carolina 4597040 29607
Greenwood 4580569, South Carolina 4597040 29646
Greer 4580599, South Carolina 4597040 29651
Hilton Head Island 4581832, South Carolina 4597040 29926
Spartanburg 4597200, South Carolina 4597040 29303
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Nashville 4644585, Tennessee 4662168 37203
Site Public Contact
615-342-1919
Nashville 4644585, Tennessee 4662168 37232
Site Public Contact
800-811-8480
Conroe 4682991, Texas 4736286 77384
Dallas 4684888, Texas 4736286 75235
Dallas 4684888, Texas 4736286 75237
Dallas 4684888, Texas 4736286 75390
Fort Sam Houston 7267736, Texas 4736286 78234
Site Public Contact
210-916-4837
Fort Worth 4691930, Texas 4736286 76104
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77079
League City 4705692, Texas 4736286 77573
Richardson 4722625, Texas 4736286 75080
San Antonio 4726206, Texas 4736286 78229
Sugar Land 4734825, Texas 4736286 77478
American Fork 5844096, Utah 5549030 84003
Cedar City 5536630, Utah 5549030 84720
Farmington 5774662, Utah 5549030 84025
Logan 5777544, Utah 5549030 84321
Murray 5778755, Utah 5549030 84107
Ogden 5779206, Utah 5549030 84403
Provo 5780026, Utah 5549030 84604
Riverton 5780557, Utah 5549030 84065
Salt Lake City 5780993, Utah 5549030 84106
Salt Lake City 5780993, Utah 5549030 84112
Salt Lake City 5780993, Utah 5549030 84143
St. George 5546220, Utah 5549030 84770
Berlin Corners 5233780, Vermont 5242283 05602
Site Public Contact
802-225-5400
Burlington 5234372, Vermont 5242283 05401
Saint Johnsbury 5240656, Vermont 5242283 05819
Charlottesville 4752031, Virginia 6254928 22908
Fairfax 4758023, Virginia 6254928 22031
Fairfax 4758023, Virginia 6254928 22033
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23230
Richmond 4781708, Virginia 6254928 23298
Seattle 5809844, Washington 5815135 98101
Vancouver 5814616, Washington 5815135 98684
Vancouver 5814616, Washington 5815135 98686
Site Public Contact
503-413-2150
Walla Walla 5814916, Washington 5815135 99362
Antigo 5244010, Wisconsin 5279468 54409
Appleton 5244080, Wisconsin 5279468 54911
Appleton 5244080, Wisconsin 5279468 54915
Ashland 5244247, Wisconsin 5279468 54806
Brookfield 5246835, Wisconsin 5279468 53045
Burlington 5247214, Wisconsin 5279468 53105
Chilton 5248469, Wisconsin 5279468 53014
Eau Claire 5251436, Wisconsin 5279468 54701
Franklin 5253710, Wisconsin 5279468 53132
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54301
Site Public Contact
920-435-8326
Green Bay 5254962, Wisconsin 5279468 54301
Green Bay 5254962, Wisconsin 5279468 54303
Green Bay 5254962, Wisconsin 5279468 54311
Johnson Creek 5257996, Wisconsin 5279468 53038
Kenosha 5258393, Wisconsin 5279468 53142
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marinette 5261852, Wisconsin 5279468 54143
Marshfield 5261969, Wisconsin 5279468 54449
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Mequon 5262649, Wisconsin 5279468 53097
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53211
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Milwaukee 5263045, Wisconsin 5279468 53233
Milwaukee 5263045, Wisconsin 5279468 53295
Site Public Contact
888-469-6614
Minocqua 5263156, Wisconsin 5279468 54548
Mukwonago 5263965, Wisconsin 5279468 53149
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Oshkosh 5265838, Wisconsin 5279468 54904
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53405
Racine 5268249, Wisconsin 5279468 53406
Rhinelander 5268720, Wisconsin 5279468 54501
Rice Lake 5268798, Wisconsin 5279468 54868
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Stevens Point 5274644, Wisconsin 5279468 54481
Stevens Point 5274644, Wisconsin 5279468 54482
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Summit, Wisconsin 5279468 53066
Two Rivers 5276609, Wisconsin 5279468 54241
Waukesha 5278052, Wisconsin 5279468 53188
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
Wauwatosa 5278159, Wisconsin 5279468 53226
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Weston 5278693, Wisconsin 5279468 54476
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT05050084
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with radiation therapy (RT) alone instead of 6 months androgen deprivation therapy (ADT) + RT experience non-inferior rate of distant metastasis. (De-intensification study) II. To determine whether men with NCCN UIR prostate cancer who are in the higher genomic risk (Decipher score >= 0.40) will have a superior metastasis-free survival through treatment intensification with darolutamide added to the standard of RT plus 6 months ADT. (Intensification study) SECONDARY OBJECTIVES: I. To compare overall survival (OS) between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. II. To compare time to prostate specific antigen (PSA) failure between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. III. To compare metastasis free survival (MFS) based on conventional imaging between the standard of care (RT plus 6 months of ADT) and de-intensification intervention (RT alone). IV. To compare MFS based on either conventional and/or molecular imaging between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. V. To compare cumulative incidence of locoregional failure based upon conventional imaging and/ or biopsy between standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months ADT plus darolutamide) interventions. VI. To compare cumulative incidence of distant metastasis based upon conventional imaging between standard of care (RT plus 6 months of ADT) and intensification intervention (RT plus 6 months ADT plus darolutamide). VII. To compare cumulative incidence of distant metastasis based upon either conventional and/or molecular imaging between standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. VIII. To compare prostate cancer-specific mortality between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. IX. To compare sexual and hormonal related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. X. To compare fatigue, as measured by the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue instrument, between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. XI. To compare cognition, as measured by the Functional Assessment of Chronic Illness Therapy-Cognitive (FACT-Cog) perceived cognitive abilities subscale, between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. EXPLORATORY OBJECTIVES: I. To compare changes in cardio-metabolic markers, including body mass index, lipids, blood glucose, complete blood count (CBC), comprehensive metabolic panel (CMP), and hemoglobin (Hgb) A1c, between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. II. To compare PSA failure-free survival with non-castrate testosterone and no additional therapies between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. III. To compare cumulative incidence of locoregional failure based upon either conventional and/or molecular imaging between standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. IV. To compare castrate-resistant prostate cancer (CRPC) between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. V. To compare bowel and urinary function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. VI. To compare time to testosterone recovery (defined as a T > 200ng/dL) between the standard of care (RT plus 6 months of ADT) and intensification (RT plus 6 months of ADT plus darolutamide) interventions. VII. To compare health utilities, as measured by the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L), between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. VIII. To develop and assess a machine learning/artificial intelligence algorithm for radiotherapy planning and/or quality assurance. IX. To perform future translational correlative studies using biological data, Decipher results, and clinical outcomes. OUTLINE: DE-INTENSIFICATION STUDY: Patients with Decipher score < 0.40 are randomized to 1 of 2 arms. ARM I: Patients undergo radiation therapy (RT) using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo RT as Arm I. Patients also receive androgen deprivation therapy (ADT) consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days. INTENSIFICATION STUDY: Patients with Decipher score >= 0.40 are randomized to 1 of 2 arms. ARM III: Patients receive treatment as in Arm II. ARM IV: Patients receive RT and ADT as in Arm II. Patients also receive darolutamide orally (PO) twice daily (BID). Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 3, 6, 12, 24, 36, 48 and 60 months.